Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05148403

To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI

Evaluation of Safety and Efficacy of Glibenclamide in the Treatment of Severe Traumatic Brain Injury

Sponsor: Beijing Tiantan Hospital

Updated 4 times since 2022 Last updated: Nov 24, 2021 Started: Oct 22, 2021 Primary completion: Oct 1, 2022 Completion: Oct 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Traumatic Brain Injury, this trial is ongoing. The trial is conducted by Beijing Tiantan Hospital and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2022 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tiantan Hospital
Beijing Tongren Hospital

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China